AN2 Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . AN2 Therapeutics
ANTX Stock  USD 1.12  0.01  0.88%   
AN2 Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing AN2 Therapeutics' valuation are provided below:
Market Capitalization
31 M
Earnings Share
(1.13)
We have found ninety-seven available fundamental measures for AN2 Therapeutics, which can be analyzed and compared to other ratios and to its peers in the sector. All investors should make sure to validate all of AN2 Therapeutics latest market performance against the performance between 2010 and 2026 to make sure the company can sustain itself this quarter and beyond.
Check AN2 Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AN2 Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 65.9 M, Interest Expense of 620.7 K or Selling General Administrative of 9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.55. AN2 financial statements analysis is a perfect complement when working with AN2 Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with AN2 Stock
Check out the analysis of AN2 Therapeutics Correlation against competitors.
For more information on how to buy AN2 Stock please use our How to Invest in AN2 Therapeutics guide.

AN2 Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets74.9 M105.9 M37.7 M
Slightly volatile
Short and Long Term Debt Total45.3 K47.7 K449.3 K
Slightly volatile
Other Current Liabilities5 M8 M2.4 M
Slightly volatile
Total Current Liabilities6.7 M11.8 M3.3 M
Slightly volatile
Total Stockholder Equity68.1 M94.1 M33.9 M
Slightly volatile
Accounts Payable4 M3.8 M1 M
Slightly volatile
Cash15.8 M24.6 M10.4 M
Slightly volatile
Cash And Short Term Investments65.1 M96.2 M33.3 M
Slightly volatile
Common Stock Shares Outstanding22.9 M34.3 M20.6 M
Slightly volatile
Liabilities And Stockholders Equity74.9 M105.9 M37.7 M
Slightly volatile
Other Current Assets1.6 M2.7 M806.7 K
Slightly volatile
Total Liabilities6.8 M11.8 M3.8 M
Slightly volatile
Total Current Assets67 M99.2 M34.3 M
Slightly volatile
Other Liabilities14.8 K11.7 K20.1 K
Slightly volatile
Net Working Capital71.1 M87.4 M30 M
Slightly volatile
Non Currrent Assets Other847.6 K723.6 K1.5 M
Slightly volatile
Other Assets0.860.91.3 M
Slightly volatile
Deferred Long Term Liabilities1.4 M1.6 M1.7 M
Slightly volatile
Property Plant And Equipment Net42.4 K47.7 K52.1 K
Slightly volatile
Non Current Liabilities Other1.6 K1.8 K2 K
Slightly volatile
Short Term Debt42.4 K47.7 K52.1 K
Slightly volatile
Net Receivables256.5 K270 K1.2 M
Slightly volatile

AN2 Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative9 M16.2 M5.3 M
Slightly volatile
Selling And Marketing Expenses17.8 M17 M6.6 M
Slightly volatile
Other Operating Expenses41.5 M62.7 M35.9 M
Slightly volatile
Research Development32.5 M46.6 M30.6 M
Slightly volatile
Total Operating Expenses41.5 M62.7 M35.9 M
Slightly volatile
Net Interest Income6.6 M6.3 M1.5 M
Slightly volatile
Interest Income6.6 M6.3 M1.5 M
Slightly volatile
Cost Of Revenue61.6 K69.3 K75.6 K
Slightly volatile

AN2 Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Cashflows From Financing Activities318.1 K334.8 K9.8 M
Very volatile
Total Cash From Financing Activities406.4 K427.8 K18.8 M
Slightly volatile
End Period Cash Flow15.8 M24.6 M10.4 M
Slightly volatile
Change To Netincome6.2 M3.4 M12.9 M
Slightly volatile
Stock Based Compensation4.9 M9.6 M2.2 M
Slightly volatile
Begin Period Cash Flow14.2 M18 M9 M
Slightly volatile
Dividends Paid1.5 M1.6 M1.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
PTB Ratio0.550.5842.1311
Slightly volatile
Book Value Per Share2.392.471.4779
Slightly volatile
PB Ratio0.550.5842.1311
Slightly volatile
Payables Turnover0.0290.03270.0356
Slightly volatile
Cash Per Share2.32.521.4565
Slightly volatile
Days Payables Outstanding8 K9.1 K9.9 K
Slightly volatile
Income Quality0.580.860.5763
Slightly volatile
Current Ratio15.859.6925.568
Slightly volatile
Tangible Book Value Per Share2.392.471.4779
Slightly volatile
Shareholders Equity Per Share2.392.471.4779
Slightly volatile
Debt To Equity6.0E-46.0E-40.0892
Slightly volatile
Graham Net Net2.082.221.303
Slightly volatile
Interest Debt Per Share0.04170.04250.0387
Very volatile
Debt To Assets6.0E-46.0E-40.0753
Slightly volatile
Price Book Value Ratio0.550.5842.1311
Slightly volatile
Days Of Payables Outstanding8 K9.1 K9.9 K
Slightly volatile
Ebt Per Ebit1.241.081.1122
Very volatile
Company Equity Multiplier1.31.291.1965
Very volatile
Long Term Debt To Capitalization0.10.120.1289
Slightly volatile
Total Debt To Capitalization6.0E-46.0E-40.0775
Slightly volatile
Debt Equity Ratio6.0E-46.0E-40.0892
Slightly volatile
Quick Ratio15.859.6925.568
Slightly volatile
Cash Ratio2.282.421.7703
Slightly volatile
Price To Book Ratio0.550.5842.1311
Slightly volatile
Debt Ratio6.0E-46.0E-40.0753
Slightly volatile
Price Fair Value0.550.5842.1311
Slightly volatile

AN2 Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap386.9 M435.2 M475 M
Slightly volatile
Enterprise Value374.3 M421.1 M459.7 M
Slightly volatile

AN2 Fundamental Market Drivers

AN2 Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About AN2 Therapeutics Financial Statements

AN2 Therapeutics investors use historical fundamental indicators, such as AN2 Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in AN2 Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue69.3 K61.6 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
MSFTMicrosoft
DDDupont De Nemours
WDWalker Dunlop

Additional Tools for AN2 Stock Analysis

When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY